Skip to main content

Viking Therapeutics stock jumps 16% after drugmaker moves weight loss injection to late-stage trial

It brings the drugmaker one step closer to joining the market for GLP-1s, which analysts say could grow into a $150 billion market by the end of the decade.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.